The candidate is currently a Research Associate in the Sidney Kimmel Cancer Center at Johns Hopkins who has previously spearheaded efforts towards discovery of new pancreatic cancer markers and the identification of invasion-specific genes in pancreatic cancers in the laboratory of Dr. Scott Kern at Johns Hopkins. The long-term career objectives of the candidate are to develop early detection markers and identify therapeutic targets for human melanoma. This research proposal uses both a mentored research training period (years 1-3) and an independent training period (years 4-5) in order for the investigator to develop gene discovery systems for human melanoma under the guidance of Drs. Rhoda Alani and Scott Kern. The investigator already has early data on promising new diagnostic/prognostic melanoma tumor markers (the HLH transcription factor, Id1 and in-situ telomere length) and therapeutic targets (Id1, telomerase) in melanoma and those will be developed as part of this proposal.
The specific aims are, therefore: 1) to identify novel markers and therapeutic targets for melanoma using gene profiling of human melanoma cell lines and primary human melanomas from varying stages of disease progression in combination with experiment-oriented data reduction algorism;2) to determine the diagnostic/prognostic significance of Id1 expression in melanocytic lesions and its utility as an indicator of malignancy and therapeutic target;3) To evaluate in-situ telomere lengths in archival samples of melanomas and determine the diagnostic/prognostic utility of telomere length in predicting biologic outcomes of melanomas in a retrospective study. The overall goal of the investigator is to transition from research in the molecular characterization of pancreatic cancers to analogous studies in human melanoma. Since melanoma is the fastest growing malignancy in the U.S. and there are no therapies that have been shown to increase life expectancy for patients with advanced disease, it is anticipated that these studies will be of high impact.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Scientist Development Award - Research & Training (K01)
Project #
5K01CA113779-05
Application #
7658296
Study Section
Subcommittee G - Education (NCI)
Program Officer
Lohrey, Nancy
Project Start
2006-07-01
Project End
2011-06-30
Budget Start
2009-07-01
Budget End
2010-06-30
Support Year
5
Fiscal Year
2009
Total Cost
$155,802
Indirect Cost
Name
Nevada Cancer Institute
Department
Type
DUNS #
557447690
City
Las Vegas
State
NV
Country
United States
Zip Code
89135
Hwang, Soonyean; Kim, Hye-Eun; Min, Michelle et al. (2015) Epigenetic Silencing of SPINT2 Promotes Cancer Cell Motility via HGF-MET Pathway Activation in Melanoma. J Invest Dermatol 135:2283-2291
Ryu, Byungwoo; Moriarty, Whei F; Stine, Megan J et al. (2011) Global analysis of BRAFV600E target genes in human melanocytes identifies matrix metalloproteinase-1 as a critical mediator of melanoma growth. J Invest Dermatol 131:1579-83
Stine, Megan J; Wang, C Joanne; Moriarty, Whei F et al. (2011) Integration of genotypic and phenotypic screening reveals molecular mediators of melanoma-stromal interaction. Cancer Res 71:2433-44
Kim, Hye-Eun; Symanowski, James T; Samlowski, Erika E et al. (2010) Quantitative measurement of circulating lymphoid-specific helicase (HELLS) gene transcript: a potential serum biomarker for melanoma metastasis. Pigment Cell Melanoma Res 23:845-8
Cummings, Staci D; Ryu, Byungwoo; Samuels, Michael A et al. (2008) Id1 delays senescence of primary human melanocytes. Mol Carcinog 47:653-9
Ryu, Byungwoo; Kim, Dave S; Deluca, Amena M et al. (2007) Comprehensive expression profiling of tumor cell lines identifies molecular signatures of melanoma progression. PLoS One 2:e594